Mid-Atlantic BioTherapeutics (MABT) was established in 2011 with the goal of eliminating devastating infectious diseases using an innovative, patented technology platform called IMT504. IMT504 utilizes the body's natural immune response to combat infections that would otherwise be challenging or impossible to address. In animal safety and efficacy models, as well as in humans, IMT504 has demonstrated remarkable outcomes. IMT504 is a genuinely groundbreaking, exclusive molecule with an exceptional safety and immunostimulatory profile in humans and various primate models.